AR126255A1 - Derivados de imidazotriazina como moduladores de il-17 - Google Patents
Derivados de imidazotriazina como moduladores de il-17Info
- Publication number
- AR126255A1 AR126255A1 ARP220101681A ARP220101681A AR126255A1 AR 126255 A1 AR126255 A1 AR 126255A1 AR P220101681 A ARP220101681 A AR P220101681A AR P220101681 A ARP220101681 A AR P220101681A AR 126255 A1 AR126255 A1 AR 126255A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- formula
- modulators
- asterisk
- formulas
- Prior art date
Links
- XZLIYCQRASOFQM-UHFFFAOYSA-N 5h-imidazo[4,5-d]triazine Chemical class N1=NC=C2NC=NC2=N1 XZLIYCQRASOFQM-UHFFFAOYSA-N 0.000 title 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- SYLTXFOKMOCILU-UHFFFAOYSA-N imidazo[1,2-b][1,2,4]triazine Chemical class N1=CC=NC2=NC=CN21 SYLTXFOKMOCILU-UHFFFAOYSA-N 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Una serie de derivados de imidazo[1,2-b][1,2,4]triazina sustituidos como se define en la presente, que son potentes moduladores de la actividad de la IL-17 humana, son, en consecuencia, beneficiosos en el tratamiento y/o prevención de diversas enfermedades humanas, que incluyen los trastornos inflamatorios y autoinmunes. Un compuesto de fórmula (1) o un N-óxido de este, o una de sus sales farmacéuticamente aceptables, Caracterizado porque E representa un grupo de fórmula (Ea), (Eb), (Ec), (Ed) o (Ee) del grupo de fórmulas (2), en los que el asterisco (*) representa el punto de unión al resto de la molécula; A representa un grupo de fórmula (Aa), (Ab), (Ac), (Ad) o (Ae) del grupo de fórmulas (3), en los que el asterisco (*) representa el punto de unión al resto de la molécula; Y representa -O-, -N(R⁷)-, -C(R⁵ᵃ)(R⁵ᵇ)-, -S-, -S(O)-, -S(O)₂- o -S(O)(N-R⁸)-; Z representa heteroarilo, tal grupo puede estar opcionalmente sustituido con uno o más sustituyentes; donde R¹, R², R³, R⁴ᵃ, R⁴ᵇ, R⁵, R⁶, R⁷ y R⁸ se definen en la reivindicación 1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2109520.3A GB202109520D0 (en) | 2021-07-01 | 2021-07-01 | Therapeutic agents |
| GBGB2203876.4A GB202203876D0 (en) | 2022-03-21 | 2022-03-21 | Therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR126255A1 true AR126255A1 (es) | 2023-10-04 |
Family
ID=82493962
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220101681A AR126255A1 (es) | 2021-07-01 | 2022-06-28 | Derivados de imidazotriazina como moduladores de il-17 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240294534A1 (es) |
| EP (1) | EP4363421A1 (es) |
| JP (1) | JP2024525044A (es) |
| AR (1) | AR126255A1 (es) |
| TW (1) | TW202317576A (es) |
| WO (1) | WO2023275301A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201909190D0 (en) * | 2019-06-26 | 2019-08-07 | Ucb Biopharma Sprl | Therapeutic agents |
| GB202210731D0 (en) | 2022-07-22 | 2022-09-07 | UCB Biopharma SRL | Therapeutic agents |
| WO2024115662A1 (en) | 2022-12-02 | 2024-06-06 | Leo Pharma A/S | Small molecule modulators of il-17 |
| GB202218846D0 (en) | 2022-12-14 | 2023-01-25 | UCB Biopharma SRL | Therapeutic agents |
| WO2024126249A1 (en) | 2022-12-14 | 2024-06-20 | UCB Biopharma SRL | Imidazotriazine derivatives as il-17 modulators |
| GB202218860D0 (en) | 2022-12-14 | 2023-01-25 | Ucb Biopharma Sprl | Therapeutic agents |
| EP4665454A1 (en) * | 2023-02-13 | 2025-12-24 | Dice Alpha, Inc. | Imidazotriazine il-17a modulators and uses thereof |
| CN121311483A (zh) * | 2023-03-28 | 2026-01-09 | 詹森药业有限公司 | 含内酰胺的咪唑并哒嗪il-17抑制剂化合物 |
| GB202305585D0 (en) | 2023-04-17 | 2023-05-31 | UCB Biopharma SRL | Therapeutic agents |
| GB202305587D0 (en) | 2023-04-17 | 2023-05-31 | UCB Biopharma SRL | Therapeutic agents |
| CN117551093B (zh) * | 2023-11-14 | 2024-06-18 | 山东天锐医药科技有限公司 | 马来酸阿伐曲泊帕起始原料4-(4-氯-2-噻吩基)-2-噻唑胺的制备方法 |
| WO2026012492A1 (en) * | 2024-07-12 | 2026-01-15 | Anew Therapeutics Pte. Ltd. | Heterocyclic compounds as il-17 inhibitors |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009204441B2 (en) | 2008-01-09 | 2015-03-05 | The Schepens Eye Research Institute, Inc. | Therapeutic compositions for treatment of ocular inflammatory disorders |
| EP2809660B1 (en) | 2012-02-02 | 2016-01-20 | Ensemble Therapeutics Corporation | Macrocyclic compounds for modulating il-17 |
| WO2014066726A2 (en) | 2012-10-26 | 2014-05-01 | Ensemble Therapeutics Corporation | Compounds for modulating il-17 |
| US10906022B2 (en) | 2016-11-22 | 2021-02-02 | Hepatochem, Inc. | Photochemistry device |
| GB201709456D0 (en) | 2017-06-14 | 2017-07-26 | Ucb Biopharma Sprl | Therapeutic agents |
| ES2963417T3 (es) | 2018-01-15 | 2024-03-27 | UCB Biopharma SRL | Derivados de imidazol condensados como moduladores de IL-17 |
| CN110511213B (zh) | 2018-05-22 | 2021-10-19 | 成都先导药物开发股份有限公司 | 一种免疫调节剂 |
| JP7349491B2 (ja) | 2018-07-12 | 2023-09-22 | ユーシービー バイオファルマ エスアールエル | Ｉｌ－１７モジュレーターとしてのスピロ環状インダン類似体 |
| GB201820165D0 (en) | 2018-12-11 | 2019-01-23 | Ucb Biopharma Sprl | Therapeutic agents |
| GB201820166D0 (en) | 2018-12-11 | 2019-01-23 | Ucb Biopharma Sprl | Therapeutic agents |
| AU2019410261B2 (en) | 2018-12-19 | 2025-10-02 | Leo Pharma A/S | Amino-acid anilides as small molecule modulators of IL-17 |
| TW202214648A (zh) | 2019-01-07 | 2022-04-16 | 美商美國禮來大藥廠 | Il-17a抑制劑 |
| US20220162191A1 (en) | 2019-03-08 | 2022-05-26 | Leo Pharma A/S | Small molecule modulators of il-17 |
| GB201909190D0 (en) | 2019-06-26 | 2019-08-07 | Ucb Biopharma Sprl | Therapeutic agents |
| GB201909194D0 (en) | 2019-06-26 | 2019-08-07 | Ucb Biopharma Sprl | Therapeutic agents |
| GB201909191D0 (en) | 2019-06-26 | 2019-08-07 | Ucb Biopharma Sprl | Therapeutic agents |
| CN112341439B (zh) | 2019-08-09 | 2022-02-15 | 成都先导药物开发股份有限公司 | 一种免疫调节剂 |
| CN112341440B (zh) | 2019-08-09 | 2022-05-31 | 成都先导药物开发股份有限公司 | 一种免疫调节剂 |
| CN112341446B (zh) | 2019-08-09 | 2022-06-17 | 成都先导药物开发股份有限公司 | 一种免疫调节剂 |
| WO2021027721A1 (zh) | 2019-08-09 | 2021-02-18 | 成都先导药物开发股份有限公司 | 一种免疫调节剂 |
| WO2021098844A1 (zh) | 2019-11-20 | 2021-05-27 | 成都先导药物开发股份有限公司 | 一种免疫调节剂 |
| WO2021170631A1 (en) | 2020-02-25 | 2021-09-02 | UCB Biopharma SRL | Difluorocyclohexyl derivatives as il-17 modulators |
| WO2021170627A1 (en) | 2020-02-25 | 2021-09-02 | UCB Biopharma SRL | Difluorocyclohexyl derivatives as il-17 modulators |
| WO2021204800A1 (en) | 2020-04-07 | 2021-10-14 | UCB Biopharma SRL | Difluorocyclohexyl derivatives as il-17 modulators |
| CN115702024A (zh) | 2020-04-07 | 2023-02-14 | Ucb生物制药有限责任公司 | 用作il-17调节剂的二氟环己基衍生物 |
| WO2022096412A1 (en) | 2020-11-09 | 2022-05-12 | UCB Biopharma SRL | Dicyclopropylmethyl derivatives as il-17 modulators |
| WO2022096411A1 (en) | 2020-11-09 | 2022-05-12 | UCB Biopharma SRL | Dicyclopropylmethyl derivatives as il-17 modulators |
| US20240140951A1 (en) | 2020-12-14 | 2024-05-02 | UCB Biopharma SRL | Imidazopyridazine derivatives as il-17 modulators |
-
2022
- 2022-06-28 AR ARP220101681A patent/AR126255A1/es unknown
- 2022-06-29 TW TW111124264A patent/TW202317576A/zh unknown
- 2022-06-30 JP JP2023580802A patent/JP2024525044A/ja active Pending
- 2022-06-30 EP EP22741247.5A patent/EP4363421A1/en active Pending
- 2022-06-30 WO PCT/EP2022/068165 patent/WO2023275301A1/en not_active Ceased
- 2022-06-30 US US18/572,274 patent/US20240294534A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240294534A1 (en) | 2024-09-05 |
| TW202317576A (zh) | 2023-05-01 |
| WO2023275301A1 (en) | 2023-01-05 |
| EP4363421A1 (en) | 2024-05-08 |
| JP2024525044A (ja) | 2024-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR126255A1 (es) | Derivados de imidazotriazina como moduladores de il-17 | |
| PE20231651A1 (es) | Compuestos para el tratamiento de enfermedades y trastornos asociados a braf | |
| CO2021002651A2 (es) | Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met | |
| CR20120389A (es) | COMPUESTOS SUSTITUIDOS DE N-(1H-INDAZOL-4-IL)IMIDAZO[1,2-a] PIRIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE cFMS | |
| MX2020008754A (es) | Compuestos farmaceuticos. | |
| PE20151332A1 (es) | Compuestos de azabencimidazol | |
| AR090005A1 (es) | Imidazo[1,2-a]pirimidinas y piridinas sustituidas | |
| AR096075A2 (es) | Derivados fusionados de pirimidina para la inhibición de la actividad quinasa de tirosina | |
| AR096979A1 (es) | Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR090230A1 (es) | Derivados macrociclicos para el tratamiento de enfermedades | |
| CY1109890T1 (el) | ΠΑΡΑΓΩΓΑ 8-ΥΠΟΚΑΤΕΣΤΗΜΕΝΗΣ-6,7,8,9- ΤΕΤΡΑΫΔΡΟΠΥΡΙΜΙΔΟ[1,2-α] ΠΥΡΙΜΙΔΙΝ-4-ΟΝΗΣ | |
| MX2019003143A (es) | Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico. | |
| MX2018003215A (es) | Derivados de imidazo[4,5-c]quinolina e imidazo[4,5-c][1,5]naftirid ina novedosos como inhibidores de lrrk2. | |
| NI201600089A (es) | Análogos de cortistatina y síntesis y usos de los mismos | |
| MX376306B (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de cinasa pim. | |
| PE20160689A1 (es) | Derivados del isocromeno como inhibidores de las fosfoinositido-3 quinasas | |
| PE20141352A1 (es) | Fenil-3-aza-biciclo[3,1,0]hex-3-il-metanonas y su uso como medicamento | |
| AR084430A1 (es) | Di/tri-aza-espiro-alcanos c | |
| AR096729A1 (es) | Derivados terapéuticamente activos de estratien-tiazol | |
| ATE528308T1 (de) | Gekoppelte azaindol-indol-derivate, herstellungsverfahren und anwendungen davon | |
| CO2019003894A2 (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia | |
| AR100713A1 (es) | Derivados de amida de compuestos de 1-oxa-4,9-diazaespiro undeceno que tienen actividad multimodal contra el dolor | |
| MX382128B (es) | Derivados de piridin-2-ona fusionados triciclicos, y su uso como inhibidores de brd4. | |
| EA201591904A1 (ru) | НОВЫЕ ПРОИЗВОДНЫЕ N-(2,3-ДИГИДРО-1H-ПИРРОЛО[2,3-b]ПИРИДИН-5-ИЛ)-4-ХИНАЗОЛИНАМИНА И N-(2,3-ДИГИДРО-1H-ИНДОЛ-5-ИЛ)-4-ХИНАЗОЛИНАМИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PERK | |
| EP4442317A3 (en) | Aminopyridine derivatives and their use as selective alk-2 inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |